06:18 AM EDT, 04/08/2024 (MT Newswires) -- BioNTech (BNTX) said Sunday that three-year follow-up data from a phase 1 trial on its immunotherapy candidate cevumeran in patients with resected pancreatic ductal adenocarcinoma, or PDAC, showed that eight out of 16 patients demonstrated an immune response associated with a longer median recurrence-free survival in cancer vaccine responders.

BioNTech Chief Medical Officer Ozlem Tureci said the data serves as an "early signal" of cevumeran's potential in PDAC. The company said the phase 1 trial evaluated the safety of cevumeran in combination with atezolizumab and standard-of-care chemotherapy in 16 patients.

A phase 2 trial on the product candidate is currently enrolling patients at clinical trial sites in the US, with additional sites planned to open globally, BioNTech added.

Price: 90.63, Change: +0.11, Percent Change: +0.12